Lycia Therapeutics

Lycia Therapeutics is a biotechnology company dedicated to developing drugs targeting protein degradation in innovative ways. The company is currently developing lysosome-targeting chimeras (LYTAC) to degrade extracellular and membrane-bound proteins, which drive a range of difficult-to-treat diseases, including cancer and autoimmune disorders. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes from circulation, and depleting antibodies against specific target antigens. This platform has the potential to deliver next-generation therapies to address a variety of hard-to-treat diseases, including cancer and autoimmune conditions.